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Atezolizumab versus chemotherapy in advanced
or metastatic NSCLC with high blood-based tumor
mutational burden: primary analysis of BFAST
cohort C randomized phase 3 trial
Solange Peters 1 ✉, Rafal Dziadziuszko2, Alessandro Morabito3, Enriqueta Felip4,
Shirish M. Gadgeel5, Parneet Cheema6, Manuel Cobo7, Zoran Andric8, Carlos H. Barrios 9,
Masafumi Yamaguchi10, Eric Dansin11, Pongwut Danchaivijitr12, Melissa Johnson 13, Silvia Novello14,
Michael S. Mathisen15, Sarah M. Shagan 15, Erica Schleifman16, Jin Wang16, Mark Yan17,
Simonetta Mocci16,20, David Voong16, David A. Fabrizio17, David S. Shames16, Todd Riehl16,21,
David R. Gandara18 and Tony Mok19
Tumor mutational burden (TMB) is being explored as a predictive biomarker for cancer immunotherapy outcomes in non-small
cell lung cancer. BFAST (NCT03178552)—an open-label, global, multicohort trial—evaluated the safety and efficacy of first-line
targeted therapies or immunotherapy in patients with unresectable Stage IIIB or IV advanced or metastatic non-small cell lung
cancer who were selected for biomarker status using blood-based targeted next-generation sequencing. In the Phase 3 cohort
C evaluating blood-based (b)TMB as a biomarker of atezolizumab efficacy, patients with bTMB of ≥10 (N = 471) were randomized 1:1 to receive atezolizumab or platinum-based chemotherapy per local standard of care. Cohort C did not meet its
primary endpoint of investigator-assessed progression-free survival in the population with bTMB of ≥16 (hazard ratio, 0.77;
95% confidence interval: 0.59, 1.00; P = 0.053). Adverse events leading to treatment withdrawal occurred in 10% of patients
in the atezolizumab arm and 20% in the chemotherapy arm. Adverse events of special interest occurred in 42% of patients
in the atezolizumab arm and 26% in the chemotherapy arm. A prespecified exploratory analysis compared the bTMB clinical trial assay with the FoundationOne Liquid Companion Diagnostic assay and showed high concordance between assays.
Additional exploration of bTMB to identify optimal cutoffs, confounding factors, assay improvements or cooperative biomarkers is warranted.

T

MB has emerged as a biomarker for cancer immunotherapy as
demonstrated by the approval of pembrolizumab for the treatment of selective solid tumors that are tissue-based (t)TMB
high1,2. TMB in both tissue and blood is currently being explored
in non-small cell lung cancer (NSCLC)3. tTMB, determined by
whole-exome sequencing, is associated with clinical benefit from
multiple checkpoint inhibitors at various cutoffs1,4–10. Assessing
TMB using large comprehensive gene panels to target a portion
of the genome has been shown to correlate with whole-exome
sequencing11–15. TMB is associated with predicted neoantigen load
and also predicts clinical benefit of anti-programmed death-ligand 1
(PD-L1)/programmed death 1 (PD-1) treatments in NSCLC5,16.
Evidence from mostly retrospective analyses of clinical trials in the
first- (1L) or second-line treatment of NSCLC suggests that TMB

predicts the efficacy of PD-L1/PD-1 inhibitor monotherapy, but not
in combination with chemotherapy3, and that tTMB is positively
correlated with bTMB17. In NSCLC, retrospective analyses have
shown TMB is independent of PD-L1 expression and seems to be
potentially predictive of progression-free survival (PFS) benefit,
but not of overall survival (OS), with checkpoint inhibitor monotherapy4,18–20. However, prospective Phase 3 trials using TMB as a
predictive biomarker are lacking.
Atezolizumab monotherapy is effective for the 1L treatment of
patients with squamous or nonsquamous advanced or metastatic
NSCLC without EGFR/ALK alterations whose tumors have high
PD-L1 expression. The Phase 3 IMpower110 trial (N = 572) enrolled
patients with NSCLC with PD-L1-positive tumors. Patients with
high PD-L1 expression, defined as ≥50% of tumor cells or ≥10%
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of tumor-infiltrating immune cells assessed by the SP142 immunohistochemistry (IHC) assay (Ventana), showed a median OS of
20.2 months with atezolizumab monotherapy versus 13.1 months
with platinum-based chemotherapy (hazard ratio (HR), 0.59; 95%
confidence interval (CI): 0.40, 0.89; P = 0.0106)18. However, OS benefit was not observed in the patient subgroup consisting of high or
intermediate PD-L1 expression (≥5% of tumor or tumor-infiltrating
immune cells). Additionally, among patients with any tumor PD-L1
expression and bTMB of ≥16 (bTMB clinical trial assay (CTA);
Foundation Medicine, Inc, Cambridge, MA), patients given atezolizumab had longer PFS than patients given chemotherapy (HR,
0.55; 95% CI, 0.33, 0.92), suggesting a cooperative predictive value
between these independent biomarkers18. Therefore, a biomarker
such as bTMB that is independent of PD-L1 and can select patients
who benefit from PD-L1/PD-1 inhibitors could help broaden
access to 1L chemotherapy-free treatment options. Furthermore,
given that up to 30% of patients have insufficient tissue at diagnosis for comprehensive biomarker testing21, a blood-based assay for
TMB that would obviate the need for tTMB analysis could identify
patients who benefit from atezolizumab therapy22.
B-F1RST (N = 152) was the first prospective Phase 2 study evaluating bTMB as a biomarker for 1L atezolizumab monotherapy
in locally advanced or metastatic NSCLC23. The primary efficacy
objective of this single-arm open-label trial was objective response
rate (ORR); the primary biomarker objective was the relationship
of investigator-assessed (INV) PFS in patients with bTMB of ≥16.
The trial met its primary efficacy endpoint but not the primary
PFS-related biomarker objective. However, incremental increases in
ORR were observed with increasing bTMB cutoffs.
The Blood First Assay Screening Trial (BFAST, NCT03178552,
ClinicalTrials.gov) is a global, open-label, multicohort trial evaluating the safety and efficacy of targeted therapies or immunotherapy
in patients with previously untreated unresectable Stage IIIB–IV
NSCLC selected for several different biomarkers, including driver
mutations and TMB, using a blood-based next-generation sequencing assay (Extended Data Fig. 1). BFAST cohort C is the first prospective randomized study to assess bTMB as a predictive biomarker
for immunotherapy. Patients were selected by bTMB status, and
atezolizumab monotherapy was compared with platinum-based
chemotherapy. bTMB status was determined by the Foundation
Medicine bTMB CTA, which was developed to evaluate TMB status
in blood samples using a hybridization capture-based method targeting 1.1 Mb (394 genes) of genomic sequence. The CTA requires
circulating free DNA to be present at a maximum somatic allele
frequency (MSAF) of ≥1% to produce reliable results17. The bTMB
CTA reports bTMB as the number of mutations detected in the targeted 1.1 Mb of sequence. The blood-based FoundationOne Liquid
(F1L) Companion Diagnostic (CDx) next-generation sequencing
assay is a United States Food and Drug Administration-approved
assay that targets 0.8 Mb and reports bTMB as the number of mutations per megabase. Here, we report primary results from BFAST
cohort C and the exploratory outcomes when using the F1L CDx
assay results.

Results

Baseline characteristics. Patients were enrolled at 120 centers
across 25 countries. From 22 September 2017 to 21 November 2019,
6,507 patients were screened, 1,437 of whom (22.1%) had a score
of bTMB of ≥10; 472 patients were enrolled in the intent-to-treat
(ITT) population and randomized to atezolizumab (n = 234) or chemotherapy (n = 237; Fig. 1). One patient randomized in error was
subsequently excluded from the analysis. The bTMB of ≥16 population included 145 patients in the atezolizumab arm and 146 in the
chemotherapy arm. The baseline demographics and characteristics
were generally balanced in both arms for the ITT and bTMB ≥16
populations (Table 1). Although patients whose tumors had ALK
1832

fusions, EGFR L858R mutations or EGFR exon 19 deletions were
excluded, other known driver alterations were potentially eligible,
and a small number of patients enrolled across the study (BRAF
V600E (n = 2), ROS1 (n = 1), RET (n = 1), HER2 exon 20 insertion
(n = 1) and EGFR exon 20 insertion (n = 1).
Efficacy in the bTMB ≥16 population. At clinical cutoff (21 May
2020), the minimum follow up in the bTMB ≥16 population was
6.0 months (median, 18.2 months). For the primary efficacy endpoint, INV-PFS, there was no significant difference in PFS between
arms, with 243 (84%) of events having occurred (stratified HR, 0.77;
95% CI: 0.59, 1.00; P = 0.053; Fig. 2a and Table 2). The median PFS
was 4.5 months (95% CI: 3.9, 5.6) for the atezolizumab arm and
4.3 months (95% CI: 4.2, 5.5) for the chemotherapy arm. The PFS
rate was 24% (95% CI: 17, 31) in the atezolizumab arm versus 7%
(95% CI: 2, 11; descriptive P < 0.0001) in the chemotherapy arm
at 12 months and 14% (95% CI: 7, 21) versus 1% (95% CI: 0, 4;
descriptive P = 0.0006), respectively, at 18 months (Fig. 2a). As the
INV-PFS did not cross the 0.05 significance boundary, secondary
endpoints were not formally tested. Subgroup analysis of PFS in the
bTMB ≥16 population was generally similar across groups, except
in patients with nonsquamous histology who showed a benefit with
atezolizumab versus chemotherapy (unstratified HR, 0.65; 95% CI:
0.48, 0.88; Fig. 3); those with squamous histology did not (unstratified HR, 1.14; 95% CI: 0.68, 1.92). In the bTMB ≥10 population,
the PFS HRs for nonsquamous (unstratified HR, 0.82; 95% CI: 0.65,
1.05) and squamous histology (unstratified HR, 1.00; 95% CI: 0.70,
1.44) had overlapping 95% CIs. OS analysis of the nonsquamous
population for atezolizumab versus chemotherapy resulted in an
unstratified HR of 0.78 (95% CI: 0.55, 1.11; Extended Data Fig. 2).
Secondary efficacy endpoints. In the bTMB ≥16 population, there
was no statistically significant improvement in OS with a median
of 13.3 months (95% CI: 8.6, 18.4) in the atezolizumab arm versus
10.3 months (95% CI: 8.5, 13.8) in the chemotherapy arm (stratified HR, 0.87; 95% CI: 0.64, 1.17; descriptive P = 0.129; Fig. 2b and
Table 2). The OS probability was 52% (95% CI: 43, 60) in the atezolizumab arm versus 42% (95% CI: 34, 51) in the chemotherapy arm
at 12 months and 42% (95% CI: 33, 52) versus 28% (95% CI: 19, 37;
descriptive P = 0.025), respectively, at 18 months (Fig. 2b). Response
rates and duration of response were improved numerically in the
atezolizumab arm. Confirmed ORR was 26% (95% CI: 19, 33;
Table 2) versus 18% (95% CI: 12, 25). Median duration of response
(DOR) was 11.9 months (95% CI: 9.5, 17.0) versus 5.7 months (95%
CI: 4.4, 10.6).
In the ITT population (bTMB ≥10), there was no difference
between treatment arms in either PFS (stratified HR, 0.91; 95% CI:
0.74, 1.11; Table 2) or OS (stratified HR, 0.99; 95% CI: 0.79, 1.25).
Median INV-PFS was 4.1 months (95% CI: 2.9, 5.2) for the atezolizumab arm versus 4.4 months (95% CI: 4.3, 5.6) in the chemotherapy arm. Median OS was 10.8 months (95% CI: 8.2, 14.0) versus
10.4 months (95% CI: 9.2, 12.2). Confirmed INV-ORR (95% CI)
was 22% (95% CI: 17, 28) versus 23% (95% CI: 18, 29). The median
DOR was 14.0 months (95% CI: 11.0, 20.8) versus 5.6 months (95%
CI: 4.9, 5.7). In the ITT population, 3.4% of patients in the atezolizumab arm and 42.2% in the chemotherapy arm received follow up
immunotherapy (Supplementary Table 1).
Safety data. The median number of doses of atezolizumab administered was 6 (range, 1–45), with a median treatment duration of
3.5 months (Supplementary Table 2). The incidence of all-grade
treatment-related adverse events was 59% with atezolizumab versus 88% with chemotherapy; the incidence of grade 3/4 events
was 18% versus 46%, respectively. Adverse events leading to treatment withdrawal occurred in 10% of patients in the atezolizumab
arm and 20% in the chemotherapy arm. Adverse events of special
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Fig. 1 | Patient flow diagram for the patient-reported outcome analyses from BFAST study cohort C. PD, progressive disease; QC, quality check.

interest occurred in 42% of patients in the atezolizumab arm and
26% in the chemotherapy arm. The most common (≥5%) were rash
(14% versus 10%), hypothyroidism (9% versus 2%) and pneumonitis (6% versus 1%; Table 3 and Supplementary Table 3).
Exploratory analysis of early disease progression. In general, this
exploratory analysis suggested that early progression (≤4 months)
in the bTMB ≥16 population was associated with greater disease
burden at baseline, as shown by the presence of more metastatic
sites or higher sum of the longest diameters (SLD) compared with
late progression (Supplementary Table 4). In the atezolizumab arm,
several characteristics were associated with early versus late progression (P < 0.1), including liver or bone metastasis, higher baseline SLD, squamous histology and presence of KEAP1 mutations. In
the chemotherapy arm, early progression was associated with liver,
adrenal gland or brain metastasis, or greater number of metastatic
sites overall, higher SLD or tumor mutations in SMARCA, ASXL1
or CDKN2A (P < 0.05).
Concordance of the F1L CDx assay with the bTMB CTA. Of the
471 patients enrolled in cohort C, 426 had samples available for
analysis with the F1L CDx assay (Extended Data Fig. 3). Of these,
403 samples passed laboratory processing and 6 failed quality control, leaving 397 samples for inclusion in the analysis. In addition
to the 397 cohort C samples, 130 CTA-negative samples (patients
screened for BFAST but not eligible for cohort C) were tested on the
F1L CDx assay to evaluate assay concordance. The bTMB CTA ≥16
cutoff was determined to be equivalent to a F1L CDx value of 13.6
mutations per megabase and ten mutations was equivalent to 8.3
mutations per megabase (Methods). The 20 most commonly
mutated genes tested by the F1L CDx assay are shown in Extended
Data Fig. 4a. This exploratory analysis showed that the two assays
were highly concordant at their respective cutoffs (Extended Data
Fig. 4b,c). Among the 245 cases that were bTMB positive according

to the CTA bTMB ≥16 cutoff (Supplementary Table 5), 203 were
also positive according to the F1L CDx assay at the bTMB ≥13.6
mutations per megabase cutoff, resulting in a positive percentage
agreement of 82.9% (203/245; 95% CI: 77.6, 87.1; Supplementary
Table 6). Among the 282 cases that were bTMB CTA negative at
the bTMB ≥16 cutoff, 258 were also F1L CDx negative, resulting in
a negative percentage agreement of 91.5% (258/282; 95% CI: 87.7,
94.2). The positive predictive value for F1L CDx was 89.4% (95% CI:
84.8, 92.8) and the overall percentage agreement was 87.5% (95%
CI: 84.4, 90.0).
An exploratory analysis compared PFS and OS between subgroups above versus below the assay-determined cutoffs, as well as
additional cutoff points at intervals of two mutations per megabase.
bTMB determined by the F1L CDx assay showed clinical concordance for PFS, with the medians and HRs for atezolizumab benefit similar to those of the bTMB CTA ≥16 cutoff. PFS in patients
above the prespecified bTMB ≥13.6 mutations per megabase cutoff according to F1L CDx was a median of 4.9 months (95% CI:
3.1, 5.8) for atezolizumab versus 4.2 months (95% CI: 4.0, 5.5) for
chemotherapy (HR 0.71; 95% CI: 0.52, 0.97; descriptive P = 0.029;
Extended Data Fig. 5a). The PFS rate was 23% (95% CI: 15, 31) in the
atezolizumab arm versus 8% (95% CI: 3, 13; descriptive P = 0.0028)
in the chemotherapy arm at 12 months, and 12% (95% CI: 5, 19)
versus 1% (95% CI: 0, 4; descriptive P = 0.0072), respectively, at 18
months (Extended Data Fig. 5a). The PFS benefit for atezolizumab
versus chemotherapy at different bTMB cutoffs as determined by
F1L CDx generally increased up to the bTMB ≥18 mutations per
megabase cutoff and then plateaued (Extended Data Fig. 5b). PFS
HRs ranged from 0.84 (95% CI: 0.66, 1.07) to 0.56 (95% CI: 0.36,
0.87) when examined as a continuous variable across increasing
bTMB cutoffs from 8.3 to 22 mutations per megabase. The optimal
HR of 0.56 was achieved at bTMB ≥20 mutations per megabase.
Median OS in patients with bTMB above the ≥13.6 mutations per megabase cutoff according to F1L CDx was 15.4 months
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Table 1 | Baseline demographics and characteristics
bTMB ≥10 (ITT)

Characteristic

bTMB ≥16

Atezolizumab N = 234

Chemotherapy N = 237

Atezolizumab n = 145

Chemotherapy n = 146

Age, median (min–max), years

66 (39–89)

66 (33–86)

65 (39–89)

66 (40–86)

Age <65 years, n (%)

108 (46)

102 (43)

72 (50)

65 (45)

Male, n (%)

170 (73)

176 (74)

106 (73)

108 (74)

White

167 (71)

173 (73)

103 (71)

106 (73)

Asian

38 (16)

43 (18)

20 (14)

32 (22)

Black

4 (2)

2 (<1)

4 (3)

1 (<1)

American Indian/Alaska Native

3 (1)

5 (2)

3 (2)

2 (1)

Native Hawaiian/Pacific Islander

1 (<1)

0

1 (<1)

0

Unknown

21 (9)

14 (6)

14 (10)

5 (3)

0

66 (28)

65 (27)

40 (28)

41 (28)

1

166 (71)

171 (72)

104 (72)

105 (72)

Race, n (%)

Baseline ECOG PS per eCRF, n (%)

3

1 (<1)

0

0

0

Unknown

1 (<1)

1 (<1)

1 (<1)

0

Tissue available (eCRF), n (%)

173 (74)

186 (78)

106 (73)

115 (79)

Never

4 (2)

4 (2)

4 (3)

2 (1)

Current

81 (35)

84 (35)

61 (42)

53 (36)

Previous

149 (64)

148 (62)

80 (55)

91 (62)

Unknown

0

1 (<1)

I

4 (2)

5 (2)

3 (2)

2 (1)

II

7 (3)

9 (4)

4 (3)

4 (3)

III

34 (15)

41 (17)

24 (17)

23 (16)

IV

189 (81)

182 (77)

114 (79)

117 (80)

Nonsquamous histology per eCRF,
n (%)

168 (72)

171 (72)

113 (78)

112 (77)

Metastatic sites, median
(min–max)

3 (1–11)

3 (1–9)

3 (1–11)

3 (1–9)

Sum of longest diameters, median
(min–max)

102 (10–253)

105 (10–246)

105 (11–253)

110 (12–246)

Liver metastases, n (%)

50 (21)

54 (23)

30 (21)

26 (18)

Brain metastases, n (%)

33 (14)

46 (19)

21 (14)

28 (19)

a

Tobacco history, n (%)

Stage at diagnosis, n (%)

eCRF, electronic case report form. aOne patient with ECOG PS 3 was inappropriately enrolled and was considered a key protocol deviation.

(95% CI: 10.2, 20.4) with atezolizumab versus 10.6 months
(95% CI: 9.1, 16.0) with chemotherapy (HR, 0.75; 95% CI: 0.53, 1.08;
Extended Data Fig. 6a). The OS rate was 56% (95% CI: 46, 65) in the
atezolizumab arm versus 45% (95% CI: 35, 54) in the chemotherapy
arm at 12 months and 47% (95% CI: 37, 58) versus 32% (95% CI: 22,
42; P = 0.034), respectively, at 18 months (Extended Data Fig. 6a).
The OS benefits with atezolizumab versus chemotherapy at different bTMB cutoffs seemed to numerically increase up to bTMB ≥12
mutations per megabase and then showed no discernible trend at
bTMB ≥13.6 mutations per megabase and above (Extended Data
Fig. 6b). OS HRs ranged from 0.97 (95% CI: 0.54, 1.75) to 0.72
(95% CI: 0.52, 1.00) when examined as a continuous variable across
increasing bTMB cutoffs from 8.3 mutations per megabase to 22
mutations per megabase. The optimal HR of 0.72 was achieved at
bTMB ≥12 mutations per megabase.
1834

Discussion

Although checkpoint inhibitor therapy has been demonstrated to
improve OS versus chemotherapy in several Phase 3 trials in the
first-line treatment of advanced stage NSCLC, only a minority of
patients sustain long-term survival benefit, regardless of PD-L1 status. Thus, there is a continuing unmet need to define additional predictive biomarkers of the efficacy of checkpoint inhibitors. In this
regard, TMB has been shown to be largely nonoverlapping and complementary to PD-L1 status in multiple retrospective analyses4,18,24,25.
BFAST is the first prospective Phase 3 trial to investigate bTMB in
this clinical setting, employing an analytically validated assay with
encouraging preliminary data in the proof-of-principle B-F1RST
study23. In B-F1RST, ORR in the ITT population was 17.1%, and
there was a trend toward longer-term benefit in the bTMB ≥16
subgroup than in the bTMB <16 subgroup, with a median PFS of
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Fig. 2 | Kaplan–Meier curve for the population of patients with bTMB ≥16. a, Primary endpoint: investigator-assessed PFS. Statistical analysis used a
stratified log-rank test at the two-sided 0.05 level and was not adjusted for multiple comparisons. b, Key secondary endpoint: OS. Statistical analysis used
a stratified log-rank test at the two-sided 0.05 level and was not adjusted for multiple comparisons. Atezo, atezolizumab; Chemo, chemotherapy. P values
for milestone PFS are descriptive.

5.0 versus 3.5 months (HR, 0.80; 90% CI: 0.54, 1.18; P = 0.35) and
a median OS of 23.9 versus 13.4 months (HR, 0.66; 90% CI: 0.40,
1.10; P = 0.18). Although there was no significant difference in PFS
observed in BFAST between atezolizumab and chemotherapy in
the population with high bTMB, progression-free rates were 24%
(95% CI: 17, 32) in the atezolizumab arm versus 7% (95% CI: 2, 11)
in the chemotherapy arm at 12 months and 14% (95% CI: 7, 21)
versus 1% (95% CI: 0.0, 4), respectively, at 18 months. Therefore,
the later timepoints for PFS may better represent the outcomes
of the study than the HR, as shown by the shape of the Kaplan–
Meier curves, suggesting that the proportional hazards assumption
may not have been met. Progression rates were initially higher in
the atezolizumab arm than in the chemotherapy arm. However,

the curves crossed at approximately 4 months and eventually
favored atezolizumab. This Kaplan–Meier ‘crossover gap’ in PFS
has been observed in multiple other Phase 3 trials of anti-PD-L1/
PD-1 monotherapy versus chemotherapy and may reflect a subset
of patients who respond better to cytotoxic chemotherapy and are
refractory to an anti-PD-L1/PD-1 agent4,9,18,26,27. Similarly, although
secondary endpoints were not formally tested, patients in the
atezolizumab arm had a numerically longer OS than the chemotherapy arm. Furthermore, a greater percentage of patients achieved
longer-term survival at 12 and 18 months, with the Kaplan–Meier
curves crossing. Moreover, the overall safety profile of atezolizumab monotherapy was consistent with that seen previously
across indications18,28.
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Table 2 | Efficacy endpoints in the bTMB ≥16 and ITT populations
bTMB ≥10

Endpoint
Atezo
n = 234

Chemo
n = 237

Median INV-PFS (95% CI), months

4.1 (2.9, 5.2)

4.4 (4.3, 5.6)

HR (95% CI)

0.91 (0.74, 1.11)

Median IRF-PFS (95% CI), months

2.8 (2.7, 4.2)

HR (95% CI)

1.22 (0.99, 1.50)

Median OS (95% CI), months

10.8 (8.2, 14.0)

HR (95% CI)

0.99 (0.79, 1.25)

Confirmed INV-ORR (95% CI), %

22 (17, 28)

OR (95% CI)

0.94 (0.61, 1.45)

Confirmed IRF-ORR (95% CI), %

23 (18, 29)a

OR (95% CI)

0.91 (0.59, 1.39)

Median INV-DOR (95% CI), months

14.0 (11.0, 20.8)
n = 52b

HR (95% CI)

0.28 (0.16, 0.50)

Median IRF-DOR (95% CI), months

12.7 (9.5, 17.0)
n = 53a

HR (95% CI)

0.57 (0.34, 0.97)

bTMB ≥16
Atezo
n = 145

Chemo
n = 146

4.5 (3.9, 5.6)

4.3 (4.2, 5.5)

0.77 (0.59, 1.00)
5.5 (4.4, 5.9)

3.6 (2.7, 5.2)

4.9 (4.2, 5.7)

1.11 (0.85, 1.45)
10.4 (9.2, 12.2)

13.3 (8.6, 18.4)

23 (18, 29)

26 (19, 33)

10.3 (8.5, 13.8)

0.87 (0.64, 1.17)
18 (12, 25)

1.57 (0.89, 2.77)
25 (19, 31)a

24 (17, 32)

20 (14, 28)

1.23 (0.70, 2.19)
5.6 (4.9, 5.7)
n = 55b

11.9 (9.5, 17.0)
n = 37b

5.7 (4.4, 10.6)
n = 26b

0.33 (0.16, 0.68)
5.7 (5.5, 7.1)
n = 57a

12.7 (9.1, 14.8)
n = 34a

5.6 (4.2, 11.9)
n = 29a

0.73 (0.36, 1.46)

Atezo, atezolizumab; Chemo, chemotherapy; IRF, independent review facility–assessed; OR, odds ratio. Atezo, n = 232; chemo, n = 232. b n is the number of patients with complete or partial response.
a

In the PFS analysis for atezolizumab versus chemotherapy in
subgroups defined by baseline disease characteristics, the nonsquamous histological group with bTMB ≥10 had an HR of 0.82 (95%
CI: 0.65, 1.05), while those with bTMB ≥16 had an HR of 0.68 (95%
CI: 0.48, 0.88). In the squamous group, those with bTMB ≥10 had
an HR of 1.00 (95% CI: 0.70, 1.44), and those with bTMB ≥16 had
an HR of 1.14 (95% CI: 0.68, 1.92). Smoking-related mutational
burden, a large contributor to overall mutation burden, is reported
to differ both quantitatively and qualitatively between squamous
lung cancers and lung adenocarcinoma. Those with squamous histology have a higher TMB and, most importantly, a more homogeneous TMB distribution than those with nonsquamous histology29.
Lung adenocarcinoma in particular displays a bimodal distribution
consisting of high mutation (smokers) and low mutation burden
(never/light-smokers and oncogene-driven cancers)30. Furthermore,
there are also qualitative differences related to highly neoantigenic
tobacco-related transversion mutations, which are more common
in squamous lung cancers29. Among patients with nonsquamous
histology in BFAST, those with bTMB ≥16 showed a greater benefit
of atezolizumab versus chemotherapy. In contrast, bTMB level was
not effective in predicting immunotherapy activity in those with
squamous histology, characterized by a more homogeneous smoking status29 and a higher TMB31 than with nonsquamous histology.
In this disease context, a distinct nonantigenic pattern of mutations,
including subclonal smoking-related alterations, might explain
the heterogenous pattern of clinical outcomes from atezolizumab
monotherapy when patients are selected based on high bTMB.
Compared with the patient populations in other studies of 1L
checkpoint inhibitor therapy, including IMpower110 (ref. 18),
CheckMate 026 (ref. 4) and 227 (ref. 25) and MYSTIC9, as well as
in real-world settings32, the population enrolled in this study, albeit
bTMB-selected, seemed to have more indicators of a poor prognosis: SLD at baseline was higher and the proportion of steroid use
required for adverse events was higher. However, the prevalence of
ever-smokers was higher, which may have contributed to greater
benefit of atezolizumab versus chemotherapy33. The rate of patients
receiving subsequent therapy (Supplementary Table 1), which may
1836

be a measure of the disease status of the enrolled population, did not
seem to be lower than has been reported for atezolizumab monotherapy in this setting18.
Analysis of early progression at a 4-month cutoff revealed
treatment-independent differences such as higher tumor burden and more metastatic sites in early versus late progressors.
Exploratory analyses showed PFS point estimates of HRs at bTMB
cutoffs above 16 mutations per megabase according to the F1L CDx
ranged from 0.56 to 0.70. OS showed only a weak trend with cutoffs
above 13.6 mutations per megabase using F1L CDx.
A formal clinical bridging study was planned if the trial was positive to establish clinical concordance between bTMB cutoffs from
the bTMB CTA and the F1L CDx assay. However, because the trial
was negative, the analytical concordance and corresponding efficacy analyses were exploratory. Interestingly, PFS in cohort C using
F1L CDx was longer with atezolizumab than with chemotherapy,
with a PFS HR of 0.71 (95% CI: 0.52, 0.96; descriptive P = 0.028).
bTMB determined by F1L CDx also showed improving PFS HRs at
higher cutoffs, suggesting that the predictive power of bTMB may be
improved by the selection of a different cutoff. This trend also suggests that bTMB is a continuous biomarker of outcomes. Selecting
a single cutoff for a biomarker of clinical response, while perhaps
more practical for clinicians to identify patients, has the disadvantage of making it more difficult to achieve statistical significance
with a given sample size. Trial designs that dichotomize the clinical
outcomes around a single cutoff can lose as much as a one-third
of their statistical power34. In contrast, adaptive trial designs that
can accommodate continuous and even nonlinear predictive effects
(that is, that increase and decrease across the bTMB range) may
more accurately model the characteristics of bTMB and be able to
categorize patients who benefit from treatment35. Furthermore, differences in the computational pipeline between the bTMB CTA and
F1L CDx may also play a role in the differences observed. Insertion
and deletion mutations (indels) were not included in the bTMB calculation for the bTMB CTA but were included in the calculation
for F1L CDx. This might have contributed to the slight differences
in clinical outcomes, due potentially to the greater association of
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Population
All patients
Age
<65 years
≥65 years
Sex
Male
Female
Race
White
Asian
American Indian or Alaska native
Black or African American
Native Hawaiian or other Pacific
Islander
Unknown
Smoking status
Previous
Current
Never
Tissue availability from IxRS
Yes
No
ECOG performance status from IxRS
0
1
Histology from IxRS
Nonsquamous
Squamous
Liver metastasis at enrollment
Yes
No
Adrenal gland metastasis at enrollment
Yes
No
Brain metastasis at enrollment
Yes
No
Bone metastasis at enrollment
Yes
No
Number of metastatic sites at enrollment
<3
≥3

n (%)

Atezo

Chemo

HR (95% CI)

291 (100.0)

4.5

4.3

0.74 (0.57, 0.95)

137 (47.1)
154 (52.9)

4.6
4.4

4.2
4.4

0.67 (0.46, 0.98)
0.78 (0.54, 1.12)

214 (73.5)
77 (26.5)

4.2
4.6

4.2
4.4

0.72 (0.53, 0.97)
0.76 (0.46, 1.26)

209 (71.8)
52 (17.9)
5 (1.7)
5 (1.7)

4.3
5.7
9.7
NE

4.4
4.1
NE
1.4

0.79 (0.58, 1.07)
0.55 (0.29, 1.07)
0.82 (0.05, 13.24)
<0.01 (0.00, NE)

1 (0.3)

4.6

NA

NA

19 (6.5)

4.7

5.7

0.96 (0.32, 2.82)

171 (58.8)
114 (39.2)
6 (2.1)

4.2
5.5
3.4

5.5
4.0
6.2

0.89 (0.63, 1.24)
0.56 (0.37, 0.86)
1.41 (0.22, 8.84)

221 (75.9)
70 (24.1)

4.6
4.2

4.2
4.8

0.77 (0.57, 1.04)
0.67 (0.40, 1.14)

81 (27.8)
210 (72.2)

5.7
4.2

5.5
4.2

0.65 (0.40, 1.06)
0.77 (0.56, 1.04)

224 (77.0)
67 (23.0)

5.3
2.9

4.2
5.6

0.65 (0.48, 0.88)
1.14 (0.68, 1.92)

56 (19.2)
235 (80.8)

1.6
5.4

3.1
5.5

0.84 (0.47, 1.50)
0.71 (0.53, 0.95)

80 (27.5)
211 (72.5)

4.4
4.5

3.0
5.5

0.67 (0.41, 1.09)
0.78 (0.57, 1.06)

49 (16.8)
242 (83.2)

3.0
4.6

2.8
5.3

0.61 (0.32, 1.16)
0.78 (0.59, 1.04)

64 (22.0)
227 (78.0)

2.7
5.5

3.9
4.4

1.15 (0.66, 2.00)
0.65 (0.48, 0.87)

95 (32.6)
196 (67.4)

5.2
4.2

5.5
4.2

0.88 (0.56, 1.40)
0.69 (0.50, 0.95)
0.1

1

10

HR
Atezo better Chemo better

100

c 100

75

75
Atezo
Chemo

50

PFS (%)

PFS (%)

b

Atezo
Chemo

50
25

25

0

0
0

2

4

6

8 10 12 14 16 18 20 22 24 26 28

0

2

4

6

Time (months)
No. at risk
Atezo 113 82 68 45 39 27 20 14 9
Chemo 111 82 56 26 10 7 4 2 2

8
1

8

10

12

14

16

18

5
2

4
1

1
1

1

Time (months)
5

4

3

2

1

No. at risk
Atezo 32
Chemo 35

19
31

15
25

9
12

7
5

5
4

Fig. 3 | Subgroup analysis of PFS in patients with a bTMB ≥16. a, Forest plot of subgroups. Error bars, 95% CI. b,c, PFS Kaplan–Meier curves for the
nonsquamous (b) and squamous (c) subgroups. Atezo, atezolizumab; Chemo, chemotherapy; lxRS, interactive voice/web response system; NA, not
analyzed; NE, not estimable.

indel mutations with antitumor antigenicity compared with SNVs,
for example36. Therefore, further study is required to validate bTMB
as a standalone biomarker for the benefit of immunotherapy.
Additional factors that can impact either the bTMB score or the
predictive power of bTMB include the overall fraction of tumor
DNA measured in the blood, and variants derived from clonal
hematopoiesis of indeterminant potential (CHIP). Patients with

very low or undetectable tumor content, as measured by MSAF,
have shown better responses and PFS with atezolizumab compared with patients who have high MSAF37. However, additional
analysis demonstrated that the favorable prognostic factors associated with MSAF seem to be the drivers for the benefit, rather
than MSAF itself37. BFAST Cohort C did not enroll low (<1%)
MSAF patients.
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Table 3 | Summary of safety for all treated patients
Adverse events, n (%)

Atezo
n = 234

Chemo
n = 221

All-grade adverse events due to any cause

216 (92)

216 (98)

Treatment-related adverse events

138 (59)

194 (88)

Grade 3/4 adverse events

107 (46)

127 (58)

Treatment-related grade 3/4 adverse events

43 (18)

102 (46)

Serious adverse events

104 (44)

82 (37)

Treatment-related serious adverse events

27 (12)

32 (14)

Grade 5 adverse events

13 (6)

12 (5)

Treatment-related grade 5 adverse events

0

3 (1)

Adverse events leading to any treatment
withdrawal

23 (10)

44 (20)

Adverse events of special interest
All-grade adverse events of special interest

95 (42)

58 (26)

Grade 3/4 adverse events of special interest

29 (12)

10 (5)

All-grade adverse events of special interest
requiring use of corticosteroids

41 (18)

20 (9)

Atezo, atezolizumab; Chemo, chemotherapy.

CHIP mutations have the potential to inflate the bTMB score,
although we estimate their impact on this assay to be mitigated for
the following reasons. First, it has been shown that CHIP variants
tend occur at low allele frequencies38,39, and the bTMB calculation
uses an allele frequency cutoff of ≥0.5%. Second, many CHIP alterations are also cancer driver mutations that are filtered from the final
bTMB score39. Therefore, low MSAF and CHIP mutations likely did
not contribute to the negative BFAST results.
Loss of heterozygosity (LOH) at the human leukocyte antigen
class I (HLA-I) locus could be a method to improve the utility
of TMB. High TMB is assumed to increase production of tumor
neoantigens and hence lead to increased specific T cell response40.
Cancer immune surveillance can be abrogated not only by exhaustion of the T cell response, but also by impaired neoantigen presentation because of somatic HLA-I LOH. TMB and HLA-I LOH are
independent predictors of OS41. However, refinements of TMB that
can account for HLA-I LOH are under investigation42.
Other factors have also been shown to induce antitumor activity via type 1 interferon and T cell recruitment, which have not
been evaluated in BFAST. For example, analyses have suggested
that cytosolic DNA fragments derived from defective DNA damage
response and repair mechanisms influence the response to immune
checkpoint inhibitors by triggering the stimulator of interferon
genes (STING) signaling pathway43,44. Notably, STK11 loss might
lead to immune evasion through methylation-induced suppression
of STING.
Although the current results based on the bTMB CTA did not
support bTMB ≥16 as a standalone predictive biomarker in 1L
immunotherapy of NSCLC, the utility of bTMB as a predictive
biomarker may be improved when combined with other relevant
biomarkers, such as genes for immune infiltration (CXCL9, CD8A,
CD274 and CXCL13)10. A recent analysis suggests that the prediction of clinical benefit using the bTMB assay may be further optimized by incorporating it into multiparameter models45.
A main limitation of this study is that PD-L1 status was not
known because tissue collection was not mandated and PD-L1 testing information was not collected from local sites. Additionally,
during the enrollment period, pembrolizumab monotherapy
was the preferred option for the 1L treatment of patients with a
1838

PD-L1-staining tumor proportion score ≥50% and was available in
many countries in combination with pemetrexed and cisplatin or
carboplatin, regardless of PD-L1 expression. Therefore, enrollment
in the trial was potentially biased considering that eligible patients
had the choice between these two pembrolizumab-based regimens
or participating in BFAST, in which the control arm was chemotherapy only. This bias potentially contributed to approximately 20% of
patients eligible by bTMB level either choosing an alternative treatment or withdrawing consent before randomization—a substantial
proportion that could have affected the external validity of the primary results. Furthermore, approximately 7% of patients in the chemotherapy arm did not receive the planned treatment. Although we
and others have shown that TMB is independent of PD-L1 IHC in
predicting the benefit of single-agent anti-PD-L1 therapy, we have
also shown that patients who are positive for both PD-L1 expression
and TMB derive the most benefit17,18. However, this raises another
limitation, namely that this incremental information provided by
bTMB adds limited benefit in the current treatment landscape
where most of the patients are already receiving anti-PD-L1 therapy.
Although we cannot be certain there was a bias against enrolling
patients with high PD-L1 expression, we believe that this likely contributed to shorter OS in the bTMB ≥16 population relative to the
same population of B-F1RST (median 13.3 versus 23.9 months)23
and, consequently, to the lack of predictive value for bTMB in
this study.
In summary, although using the bTMB CTA at a cutoff of ≥16
was not a predictive biomarker for atezolizumab outcome as tested
in this study, the 18-month PFS and OS both numerically favored
atezolizumab in the bTMB ≥16 group. By using the F1L CDx
assay at an equivalent cutoff of bTMB ≥13.6 mutations per megabase, atezolizumab showed improved PFS versus chemotherapy.
Additional exploration of bTMB to identify and validate optimal
cutoffs or employ new adaptive trial designs to accommodate the
continuous and complex nature of bTMB are warranted, as are studies to account for confounding factors such as HLA-I LOH. bTMB
may have utility in combination with other relevant biomarkers (for
example, PD-L1 status) to identify subgroups that may be responsive to 1L treatment with checkpoint inhibitors in NSCLC17,18.
Further studies are needed to explore such associations.
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Methods

Study design and patients. BFAST is an ongoing global, open-label, multicohort
trial. Cohort C used a randomized, Phase 3 trial design. The study protocol is
available as a Supplementary file. Eligible patients were aged ≥18 years, had
previously untreated histologically or cytologically confirmed unresectable
Stage IIIB or IV NSCLC according to the American Joint Committee on Cancer
Staging version 7, Eastern Cooperative Oncology Group (ECOG) Performance
Status (PS) of 0 or 1, measurable disease per Response Evaluation Criteria in Solid
Tumors (RECIST) v.1.1, bTMB ≥10 mutations (8.3 mut Mb–1) as detected via
the bTMB CTA and a treatment-free interval of ≥6 months if they had received
previous neoadjuvant or adjuvant treatment. Key exclusion criteria included
untreated brain metastasis, history of malignancy other than NSCLC in the past
5 years and presence of an oncogenic EGFR mutation or ALK fusion. As the goal of
this study was to evaluate bTMB as a predictive biomarker to identify treatment for
most of the patients in the 1L setting, including those who are not able to submit
adequate tissue for molecular profiling, tissue was not required for enrollment.
However, patients were stratified by investigator-reported tissue availability. Due
to the umbrella design of the trial, in which numerous therapies were tested
in biomarker-selected populations, results of local biomarker tests were not
collected because of the number of tests available. Patients were also stratified by
bTMB cutoff (bTMB ≥16 (13.6 mut Mb–1) versus between bTMB ≥10 and bTMB
<16), ECOG PS (1 versus 0) and histology (nonsquamous versus squamous).
Cancer driver genes were defined based on their status in the Catalog of Somatic
Mutations in Cancer46 or evidence from literature supporting their pathogenicity
status. This literature evidence must demonstrate that the mutations in the tumor
suppressor gene results in loss of function. The cancer driver genes are maintained
in a database at Foundation Medicine Inc. (FMI) that is updated over time as
new clinical evidence emerges. Pathogenic mutations in CHIP-related genes were
filtered from the bTMB calculation. Single nucleotide substitutions detected at an
allele frequency of ≥0.5% were filtered for germline and driver mutations and were
included in the bTMB score17. Samples with low tumor content within a circulating
free DNA sample as measured by MSAF < 1%, were below the limit required to
make reproducible bTMB determinations. bTMB was shown to be a continuous
variable, and a cutoff of bTMB ≥16 was selected for further investigation based on
a retrospective analysis of PFS in patients with NSCLC treated with second-line or
later atezolizumab monotherapy17,47. Validation of the assay using Phase 3 data in
the second-line or later NSCLC treatment setting48 showed PFS benefit at bTMB
≥16 (HR, 0.65; 95% CI: 0.47, 0.92), and the lowest cutoff with PFS benefit was
bTMB ≥10 (HR, 0.73; 95% CI: 0.56, 0.95)17. Based on these results, BFAST cohort
C defined the bTMB CTA enrollment criterion as bTMB ≥10 mutations, and the
primary endpoint was evaluated at the bTMB ≥16 cutoff. Enrolling at the bTMB
≥10 cutoff while stratifying at the bTMB ≥16 cutoff enabled clinical evaluation of
multiple cutoffs within cohort C.
The study was conducted in accordance with the guidelines for Good Clinical
Practice and the Declaration of Helsinki, and all patients provided written
informed consent. The study protocol was approved by institutional review
boards of participating institutions, including the Ontario Cancer Research Ethics
Board (OCREB) (Princess Margaret Cancer Center, William Osler Health System
Brampton Civic Hospital, and Sunnybrook Health Sciences Center) and the
University of Saskatchewan Biomedical Research Ethics Board (Saskatoon
Cancer Centre).
Study treatment. Patients were randomized 1:1 by a stratified permuted-block
randomization procedure via interactive voice or Web-based response system
to receive atezolizumab 1,200 mg intravenously (IV) every 3 weeks until disease
progression or loss of clinical benefit, or platinum-based chemotherapy every
3 weeks for four or six cycles per local standard of care. Patients with nonsquamous
disease received pemetrexed 500 mg m–2 in combination with cisplatin (75 mg m–2)
or carboplatin (area under the concentration curve 5 or 6) IV with optional
maintenance pemetrexed allowed. Patients with squamous disease received
gemcitabine 1,250 mg m–2 plus cisplatin 75 mg m–2 or gemcitabine 1,000 mg m–2 plus
carboplatin area under the concentration curve 5 IV for four or six cycles per local
standard of care.
Assessments. The primary endpoint evaluated in the bTMB ≥16 population, as
determined by the bTMB CTA, was INV-PFS, defined as time from randomization
to disease progression according to RECIST 1.1 or death. Secondary endpoints
included OS, defined as time from randomization to death from any cause, in the
bTMB ≥16 population, INV-PFS and OS in the bTMB ≥10 (ITT) population, PFS
by independent review, ORR and DOR by INV and independent review. Safety
and tolerability were assessed by incidence, type and severity of adverse events
according to the National Cancer Institute Common Terminology Criteria for
Adverse events v.4.0. A post hoc exploratory analysis compared the bTMB CTA
used to select patients in BFAST with the F1L CDx assay, and clinical outcomes
were analyzed in patients who were bTMB positive (13.6 mut Mb–1) by F1L CDx.
Statistical analysis. Approximately 440 patients were planned to be enrolled in
the bTMB ≥10 population, including 280 in the bTMB ≥16 population based on
a one-sided significance level of 0.025 each for the comparison in the bTMB ≥10
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and bTMB ≥16 populations and 95% power to detect an HR of 0.6 in the bTMB
≥16 population and 0.65 in the bTMB ≥10 population. The primary PFS endpoint
in the bTMB ≥16 population was statistically tested at the α = 0.05 two-sided
significance level using a stratified Cox regression model to estimate effect size
and a log-rank test to calculate P values. Stratification factors for the bTMB
≥16 population were ECOG PS (0 versus 1), histology (nonsquamous versus
squamous), and tissue availability (yes versus no). In the bTMB ≥10 population,
the stratification factors were ECOG PS (0 versus 1), histology (nonsquamous
versus squamous), bTMB cutoff (bTMB ≥10 to <16 versus bTMB ≥16), and
tissue availability (yes versus no). If significant, the secondary endpoints were
hierarchically tested at the two-sided α = 0.05 significance level (for each endpoint)
in the order of OS in the bTMB ≥16 population, PFS in the bTMB ≥10 population
then OS in the bTMB ≥10 population. Clinical analyses were performed using SAS
(v.9.4). Biomarker exploratory analyses were performed using R (v.3.6.1).
Exploratory analyses. Early disease progression. To explore factors associated with
early disease progression, patients whose disease had progressed within 4 months
were analyzed for baseline characteristics and genomic alterations. The analysis
included the bTMB ≥16 population and was performed in each treatment arm,
and in both arms combined, with a significance cutoff of P < 0.1. Fisher’s exact test
was used to assess the association between early disease progression and binary
clinical variables. For continuous clinical variables, a t-test was used.
Concordance between the bTMB CTA and F1L CDx assays. The F1L CDx assay was
intended to be the assay for CDx registration but was not available at the time of
study start. Per the prespecified statistical analysis plan, a clinical bridging study
would have been executed to bridge the efficacy of the study from the bTMB
CTA to the CDx. However, due to the negative outcome of the primary endpoint,
only an analytical concordance was performed with the bTMB CTA, and efficacy
analyses were exploratory.
The analysis set for the concordance study comprised available samples from
all enrolled patients, excluding those who withdrew consent, for a F1L CDx
biomarker-evaluable population of 426 (Extended Data Fig. 3). CTA-negative
(bTMB <10) samples from patients screened for BFAST who were ineligible for
enrollment in cohort C were also tested with the F1L CDx assay. The bTMB CTA–
determined bTMB scores were converted to mutations per megabase (the metric
used in the F1L CDx assay) by factoring the size of the T7 bait set (FMI) targets
(~1.14 Mb) and then adjusting for ambiguity related to rounding using a −0.5
correction factor. Cutoffs for the prespecified analysis at bTMB ≥10 and bTMB
≥16 were calculated according to the following equations:
(16 mut − 0.5)/1.14 Mb = 13.60 mut Mb
(10 mut − 0.5)/1.14 Mb = 8.33 mut Mb

−1

−1

The overall, positive and negative percentage agreements were calculated,
as well as the naive estimates of positive and negative predictive values49, using
prevalence counts reported in Supplementary Table 5; 95% CIs were calculated
using the Wilson method. PFS and OS were compared between atezolizumab and
chemotherapy at the prespecified cutoffs of bTMB ≥13.6 mutations per megabase
and bTMB ≥8.3 mutations per megabase and then by various additional cutoffs.
Assessments. Tumor assessments per RECIST v.1.1 were conducted using
computed tomography scans with contrast or magnetic resonance imaging at
baseline, every 6 weeks (±1 week) for the first 48 weeks following treatment
initiation and then every 9 weeks thereafter, regardless of dose delays, until disease
progression per RECIST v.1.1 or loss of clinical benefit for patients receiving
atezolizumab past disease progression. Whole blood for laboratory assessments
was collected at screening, Day 1 (±3 days) of each treatment cycle and
discontinuation. The incidence and severity of adverse events were assessed using
the National Cancer Institute Common Terminology Criteria for Adverse Events
v.4.0 at each patient contact.
Reporting summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.

Data availability

As this study is ongoing, access to patient-level data from this trial will not be
available until at least 18 months after the last patient visit and a clinical study
report has been completed. After that time, requests for data will be assessed by an
independent review panel, which decides whether or not the data will be provided.
Once approved, the data are available for up to 24 months. At the time of writing
this request platform is Vivli: https://vivli.org/ourmember/roche/. For up-to-date
details on Roche’s Global Policy on the Sharing of Clinical Information and how
to request access to related clinical study documents, see: https://go.roche.com/
data_sharing. Anonymized records for individual patients across more than one
data source external to Roche cannot be linked due to a potential increase in risk
of patient reidentification. The FMI database of known driver mutations can
Nature Medicine | www.nature.com/naturemedicine
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be requested for access by contacting the FMI study review committee at src@
foundationmedicine.com, where proposals are reviewed monthly and subject
to data sharing agreements imposed by FMI until further notice. Figures with
associated raw data include main text Figs. 1–3, main Tables 1–3, Extended Data
Fig. 2–6 and Supplementary Tables 1–6.
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Extended Data Fig. 1 | BFAST study design. bTMB, blood-based tumor mutational burden; ECOG PS, Eastern Cooperative Oncology Group performance
status; eCRF, electronic case report form; q3w, every 3 weeks; R, randomized. aOne patient was excluded from the analysis population due to
randomization by error.
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Extended Data Fig. 2 | Subgroup analysis of overall survival in patients with a blood-based tumor mutational burden ≥16. (A) Forest plot of subgroups.
Error bars indicate 95% confidence intervals. (B) Kaplan-Meier curves for the non-squamous subgroup. Atezo, atezolizumab; Chemo, chemotherapy;
ECOG, Eastern Cooperative Oncology Group; IxRS, interactive voice/web response system; NA, not analyzed; NE, not estimable.
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Extended Data Fig. 3 | Sample flow for the concordance study comparing the bTMB CTA and F1L CDx assay for bTMB ≥10 and for bTMB ≥16. Sample
flow for the concordance study comparing the bTMB CTA and F1L CDx assay for (A) bTMB ≥10 and for (B) bTMB ≥16. The bTMB ≥16 samples are a
subset of the bTMB ≥10 samples. BEP, biomarker-evaluable population; bTMB, blood-based tumor mutational burden; CTA, clinical trial assay; F1L CDx,
FoundationOne Liquid Companion Diagnostic. aExcludes patients who withdrew consent or with unavailable samples. b6 samples failed quality check. c3
samples failed quality check.
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Extended Data Fig. 4 | Prevalence of the 20 most commonly mutated genes in the F1L CDx-evaluable patient population and comparison of the
corrected bTMB CTA and F1L CDx bTMB values. (A) Prevalence of the 20 most commonly mutated genes in the F1L CDx-evaluable patient population
(n = 398). Known and likely alterations in genes with allele frequencies ≤35% are presented. (B) Comparison of the corrected bTMB CTA and F1L CDx
bTMB values. (C) An expanded graph showing cases near the cutoff. Concordant cases are shown in the shaded region. a These genes are known to
accumulate CHIP alterations, which is noted in the F1L CDx report, and are filtered from the bTMB calculation.

Nature Medicine | www.nature.com/naturemedicine

Nature Medicine

Extended Data Fig. 5 | See next page for caption.
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Extended Data Fig. 5 | Exploratory analysis of PFS in subgroups defined by the F1L CDx assay PFS survival curves for the bTMB ≥13.6 mut/Mb
population atezolizumab arm vs chemotherapy arm and PFS HRs at various cutoffs. Exploratory analysis of PFS in subgroups defined by the F1L CDx
assay (A) PFS survival curves for the bTMB ≥13.6 mut/Mb population atezolizumab arm vs chemotherapy arm. Statistical analysis used a stratified
log-rank test at the two-sided 0.05 level and was not adjusted for multiple comparisons. (B) Forest plot of PFS HRs at various bTMB cutoffs. Atezo,
atezolizumab; bTMB, blood-based tumor mutational burden; Chemo, chemotherapy; F1L CDx, FoundationOne Liquid Companion Diagnostic assay;
HR, hazard ratio; PFS, progression-free survival. P values are descriptive.
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Extended Data Fig. 6 | See next page for caption.
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Extended Data Fig. 6 | Exploratory analysis of OS in subgroups defined by the F1L CDx assay OS survival curves for the bTMB ≥13.6 mut/Mb
population atezolizumab arm vs chemotherapy arm and OS HRs at various bTMB cutoffs. Exploratory analysis of OS in subgroups defined by the F1L
CDx assay (A) OS survival curves for the bTMB ≥13.6 mut/Mb population atezolizumab arm vs chemotherapy arm. Statistical analysis used a stratified
log-rank test at the two-sided 0.05 level and was not adjusted for multiple comparisons. (B) Forest plot of OS HRs at various bTMB cutoffs. Atezo,
atezolizumab; bTMB, blood-based tumor mutational burden; Chemo, chemotherapy; F1L CDx, FoundationOne Liquid Companion Diagnostic assay;
HR, hazard ratio; OS, overall survival; PFS, progression-free survival. P values are descriptive.
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